Man Group
ACAD icon

Man Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Man Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312K Sell
12,332
-117,052
-90% -$2.58M ﹤0.01% 2164
2026
Q1 		$2.88M Sell
129,384
-218,776
-63% -$5.23M 0.01% 1409
2025
Q4 		$9.3M Sell
348,160
-29,013
-8% -$693K 0.02% 832
2025
Q3 		$8.05M Buy
377,173
+90,240
+31% +$2.13M 0.01% 883
2025
Q2 		$6.19M Buy
286,933
+90,615
+46% +$1.68M 0.01% 969
2025
Q1 		$3.26M Sell
196,318
-1,024,704
-84% -$18.6M 0.01% 1180
2024
Q4 		$22.4M Sell
1,221,022
-54,411
-4% -$878K 0.06% 388
2024
Q3 		$19.6M Buy
1,275,433
+1,218,288
+2,132% +$20.3M 0.05% 461
2024
Q2 		$929K Buy
57,145
+6,844
+14% +$110K ﹤0.01% 1533
2024
Q1 		$930K Buy
50,301
+18,081
+56% +$448K ﹤0.01% 1571
2023
Q4 		$1.01M Buy
+32,220
New +$769K ﹤0.01% 1444
2023
Q3 		– Sell
-277,196
Closed -$7.53M – 1217
2023
Q2 		$6.64M Buy
+277,196
New +$6.16M 0.02% 765
2023
Q1 		– Sell
-955,688
Closed -$18.2M – 472
2022
Q4 		$15.2M Buy
955,688
+932,503
+4,022% +$14.6M 0.05% 415
2022
Q3 		$379K Buy
+23,185
New +$375K ﹤0.01% 1600
2022
Q2 		– Sell
-19,436
Closed -$470K – 2024
2022
Q1 		$470K Buy
+19,436
New +$470K ﹤0.01% 1602
2021
Q1 		– Sell
-50,129
Closed -$2.68M – 1829
2020
Q4 		$2.68M Sell
50,129
-9,131
-15% -$453K 0.01% 1087
2020
Q3 		$2.44M Sell
59,260
-56,160
-49% -$2.43M 0.01% 1124
2020
Q2 		$5.59M Buy
115,420
+65,835
+133% +$3.16M 0.03% 612
2020
Q1 		$2.1M Sell
49,585
-37,732
-43% -$1.55M 0.01% 867
2019
Q4 		$3.73M Buy
+87,317
New +$3.8M 0.01% 1104
2019
Q2 		– Sell
-48,215
Closed -$1.29M – 1867
2019
Q1 		$1.29M Sell
48,215
-1,646
-3% -$38.4K ﹤0.01% 1497
2018
Q4 		$806K Buy
+49,861
New +$968K ﹤0.01% 1520
2018
Q2 		– Sell
-6,314
Closed -$142K – 2093
2018
Q1 		$142K Buy
+6,314
New +$175K ﹤0.01% 1947

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Man Group's ACAD Position: Q2 2026 in Review

Man Group reduced its Acadia Pharmaceuticals (ACAD) stake by 90% in Q2 2026, selling an estimated $2.58M and leaving 12,332 shares worth $312K. The position accounts for ﹤0.01% of the portfolio, ranked #2164.

Man Group first reported a position in ACAD in Q1 2018 and has held it in 23 quarters since. The position peaked at $22.4M in Q4 2024. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Man Group held 12,332 shares of Acadia Pharmaceuticals worth $312K as of Q2 2026.
  • Man Group sold 117,052 Acadia Pharmaceuticals shares in Q2 2026, an estimated $2.58M.
  • Acadia Pharmaceuticals made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #2164 holding.
  • Man Group first reported a position in Acadia Pharmaceuticals in Q1 2018 and has held it in 23 quarters since.
  • Man Group's Acadia Pharmaceuticals position peaked at $22.4M in Q4 2024.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.